Exploring the Future of Gene Therapy and Longevity with Elizabeth Parish

In a groundbreaking conversation on the Empowering Neurologist, Dr. David Perlmutter sits down with Elizabeth Parish, CEO of Bioviva, to discuss her pioneering work in gene therapy and its implications for human aging. Elizabeth holds the title of the first genetically modified human, sparking global debate and curiosity about the potential of biotechnology to redefine aging as a treatable condition.

The Intersection of Gene Therapy and Aging

Elizabeth Parish’s journey into the world of gene therapy began in 2013 when she started advocating for stem cell therapy. After her son was diagnosed with type 1 diabetes, she realized the urgent need for innovative medical solutions for childhood diseases. This led her to a conference on aging, where she became fascinated with the idea of treating aging itself as a disease.

A New Perspective on Aging

Parish argues that aging should not be seen merely as a chronological process but rather as a biological one, with cellular degeneration leading to various diseases. By addressing the underlying biological aging, she believes we can improve both lifespan and healthspan.

Gene Therapies: A New Frontier

In 2015, Elizabeth launched Bioviva, with the goal of developing gene therapies that could potentially reverse aspects of biological aging. She personally underwent the first human gene therapy, receiving treatments aimed at lengthening telomeres and enhancing muscle growth. She discusses the implications of these therapies not just for aging but also for childhood diseases.

Key Gene Therapies Discussed

• Telomerase Reverse Transcriptase: Aims to lengthen telomeres, which are crucial for cellular division and aging.
• Follistatin: Inhibits myostatin, potentially enhancing muscle growth and function.
• Alpha-Klotho: Associated with cognitive function and longevity, showing promise for Alzheimer's treatment.
• PGC-1 Alpha: Enhances mitochondrial function, which is crucial for energy metabolism and brain health.

Challenges and Future Directions

Despite the promising results, Elizabeth acknowledges the controversy surrounding her approach. Critics argue that her actions were risky and could set a dangerous precedent. However, she remains undeterred, emphasizing the need for innovative solutions to combat biological aging. Her work aims to establish regulatory pathways for gene therapies, making them accessible and safe for patients.

Key Takeaways from This Discussion

• Biological aging can be treated as a disease, with gene therapies providing potential solutions.
• Elizabeth Parish is a trailblazer in the field of gene therapy, advocating for innovative treatments for both aging and childhood diseases.
• Successful gene therapies have shown improvements in healthspan and lifespan, challenging traditional views on aging.
• Future research will continue to explore combinatorial gene therapies to enhance human health and longevity.

Conclusion

As Elizabeth Parish continues to push the boundaries of biotechnology, her work opens the door to a new era of medicine where aging could be seen as a modifiable condition. The insights shared in this conversation highlight the importance of innovation in addressing aging and its associated diseases, paving the way for a healthier future.

To stay updated on Elizabeth Parish's work and advancements in gene therapy, follow Bioviva’s social media channels and explore the emerging landscape of biotechnology.